MAIA Biotechnology, Inc.
4444 West Lake Street, Suite 1700
Chicago, IL 60606
April 21, 2023
VIA EDGAR & TELECOPY
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
Washington, D.C. 20549
Attention: Jimmy McNamara
|
RE: |
MAIA Biotechnology, Inc. (the “Company”) |
|
|
Registration Statement on Form S-1 (File No. 333-269606) (the “Registration Statement”) Request for Acceleration of Effective Date
|
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), the Company requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement become effective on April 24, 2023 at 5:30 p.m., Eastern Time, or as soon as practicable thereafter, or at such later time as the Company or its counsel may request via telephone call to the staff. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.
|
|
Very truly yours, |
||
|
|
|
||
|
|
By: |
/s/ Vlad Vitoc |
|
|
|
|
Name: |
Vlad Vitoc |
|
|
|
Title: |
Chief Executive Officer |
|
cc: |
Angela Dowd, Esq., Loeb & Loeb LLP
|